Narrowband UVB light therapy with tacrolimus or calcipotriol for vitiligo
Treatments studied
Part of Skin clinical trials.
This study compares two treatments for vitiligo: narrowband UVB light therapy combined with either tacrolimus ointment or calcipotriol ointment. It aims to see which combination works better and is safer for people with stable, limited vitiligo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have localized vitiligo (patches on limited areas of the body)
- You are between 15 and 70 years old
- Your vitiligo involves no more than 20% of your body surface
- Your vitiligo has been stable (no new or spreading patches) for at least 3 months
- You are not pregnant or breastfeeding
- You do not have skin cancer or other serious skin diseases, and you have not had an allergic reaction to tacrolimus or calcipotriol
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gel called latanoprost for teens with stable vitiligo. It looks at whether the gel helps bring back color to white patches on the skin.
This trial tests whether combining microneedling (tiny needle pricks to stimulate skin) with minoxidil cream, with or without special UV light therapy, can help restore skin color in people with stable vitiligo. It aims to find the most effective treatment combination for this skin condition.
This trial compares two medicines—oral tacrolimus and dexamethasone micro-pulse therapy—in children aged 4 to 12 whose vitiligo is spreading quickly. The goal is to see which treatment works better to stop the spread and help color return to the skin.
This study compares two treatments for widespread vitiligo: a light therapy combined with a medicine called psoralen (PUVA) versus a pill called tofacitinib. It will help find which option works better and is safer for people with stable, extensive vitiligo.
This trial tests whether combining narrowband UVB light with topical steroids can help treat vitiligo, and looks at specific blood markers (CXCL11 and TEMRA) to see how the treatment affects the immune system. It may help patients with stable, non-segmental vitiligo who have not used systemic therapy in the last 3 months.
This trial tests whether adding a daily nasal spray (Melanotan II) to light therapy helps restore color in stable vitiligo patches. It may be a good option for adults with mild to moderate nonsegmental vitiligo that hasn't changed in at least 6 months.
Hear when a new Vitiligo - Macular Depigmentation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.